In a phase 2 clinical trial to assess the effectiveness of olaparib for metastatic prostate cancer and gastric cancer, ATM mutated cases had better prognosis than ATM wildtype cases35,36. This evidence concerns the gene ATM and metastatic prostate carcinoma.